Medical Device Manufacturing / Respiratory Support Technology
Strategic Profile
Vapotherm is a pioneer in mask-free respiratory support technology, operating as the market leader in high velocity therapy devices. The company generates revenue through direct hospital sales in the US and international distribution, serving a critical niche in respiratory care with proven clinical outcomes and patient comfort advantages over conventional mask-based therapies.
Cyborg Score Rationale
While Vapotherm holds strong market position and differentiated technology in respiratory care, the company faces significant headwinds including a delisting from NYSE to OTC markets (Dec 2023), pending going-private transaction at $2.18/share, and revenue challenges evidenced by relatively modest revenue base around $68.67M for its market position.
Top Insights
Company is undergoing a definitive merger agreement to go private at $2.18/share (166% premium over June 2024 price), representing major strategic inflection
Delisting from NYSE to OTC markets (December 2023) reflects market capitalization or compliance challenges despite strong clinical traction
Over 4.4 million patients treated with Vapotherm systems represents substantial real-world adoption and clinical validation
Mask-free respiratory support technology provides differentiated competitive advantage vs. mask-based conventional therapies in market with high switching costs once established in hospitals
Named Competitors
Fisher & Paykel Healthcare — Diversified respiratory support and humidification systems manufacturer
ResMed — Global leader in cloud-connected medical devices for respiratory, software as a service (SaaS)
Drägerwerk — German-based medical and safety equipment manufacturer specializing in respiratory care
Becton Dickinson — Diversified medical technology company with respiratory care portfolio
Recent Developments
(June 2024) Company entered definitive merger agreement to go private with investor group led by Perceptive Advisors at $2.18 per share
(December 2023) Vapotherm transferred listing from NYSE to OTC Pink Markets
(January 2022) Company completed acquisition/merger with ResCare respiratory division
Open the full interactive Vapotherm, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.